Increasing the evidence of
antiproliferative effect of Lanreotide
• Randomized Phase III study (NCT02683941)
– Lanreotide 120 mg every 28 days vs placebo (SPINET)
• Non-Randomized Phase II study (NCT02651987)
– Lanreotide 120 mg every 14 days (CLARINET FORTE)
• Randomized Phase II study (NCT01731925)
– Lanreotide 120 mg every 28 days +/- sunitinib (SUNLAND)
• Non-Randomized Phase II study (NCT02231762)
– Lanreotide 120 mg + Temozolomide (ATLANT)
• Randomized Phase II/III study (NCT02288377)
– Maintenance after 1
st
line Lanreotide 120 mg vs placebo (REMINET)
